Seminars in Oncology
Volume 31, Issue 4 , Pages 574-587, August 2004

Treatment of metastatic esophagus and gastric cancer

  • Manish A. Shah

      Affiliations

    • Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan- Kettering Cancer Center and the Weil School of Medicine of Cornell University, New York, NY, USA
    • Corresponding Author InformationAddress reprint requests to Manish A. Shah, MD, Gastrointestinal Oncology Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Ave, New York, NY 10021 USA
  • ,
  • Gary K. Schwartz

      Affiliations

    • Department of Medicine, Gastrointestinal Oncology Service, Memorial Sloan- Kettering Cancer Center and the Weil School of Medicine of Cornell University, New York, NY, USA

Abstract 

Cancers of the upper gastrointestinal tract include cancers of the esophagus, gastroesophageal junction, and stomach. Metastatic or unresectable upper gastrointestinal malignancies are incurable but do benefit from palliative chemotherapy. Several agents have been examined in the treatment of these diseases, with modest single-agent activity. In combination, these chemotherapeutic agents demonstrate improved antitumor activity with acceptable toxicity. Several combination therapies have been developed and have been examined in recent large phase III randomized clinical trials. These studies, for the most part, have failed to demonstrate a survival advantage over the reference arm. However, with the examination of newer cytotoxic agents, as well as with the application of molecularly targeted approaches to upper gastrointestinal malignancies, there remains hope for improved therapies for these diseases in the future.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0093-7754(04)00234-9

doi:10.1053/j.seminoncol.2004.04.013

Seminars in Oncology
Volume 31, Issue 4 , Pages 574-587, August 2004